Developing new treatments for diabetes using 12-lipoxygenase inhibitors.
Development of 12-Lipoxygenase Inhibitors for diabetes treatment.
['FUNDING_OTHER'] · VA NORTHERN CALIFORNIA HEALTH CARE SYS · NIH-11186202
This study is looking at a special enzyme that can make diabetes worse, especially in veterans who have had COVID-19, and it's testing a new treatment that might help improve insulin function and prevent diabetes from getting worse.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VA NORTHERN CALIFORNIA HEALTH CARE SYS (nih funded) |
| Locations | 1 site (MATHER, UNITED STATES) |
| Trial ID | NIH-11186202 on ClinicalTrials.gov |
What this research studies
This research focuses on developing inhibitors for the enzyme 12-lipoxygenase, which is linked to diabetes complications. The study aims to understand how this enzyme affects pancreatic beta cells and contributes to diabetes progression, particularly in veterans who have experienced COVID-19. By using advanced screening techniques, researchers have identified a promising inhibitor that could potentially improve insulin signaling and prevent the onset of diabetes. The research will involve laboratory experiments and may lead to new therapeutic options for managing diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults, particularly veterans, who have been diagnosed with diabetes or are at risk of developing it.
Not a fit: Patients who do not have diabetes or are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of diabetes and its complications.
How similar studies have performed: Previous research has shown that targeting 12-lipoxygenase can improve insulin signaling in animal models, indicating potential for success in human applications.
Where this research is happening
MATHER, UNITED STATES
- VA NORTHERN CALIFORNIA HEALTH CARE SYS — MATHER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NADLER, JERRY L. — VA NORTHERN CALIFORNIA HEALTH CARE SYS
- Study coordinator: NADLER, JERRY L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: adult onset diabetes, Adult-Onset Diabetes Mellitus, after COVID-19 infection, after infection by SARS-CoV-2